Bioniche, Endo Pharmaceuticals Sign Licensing Agreement For Urocidin
Published: 10-Jul-2009
Bioniche would manufacture the product and receive a transfer price for supply
Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin in the US, with an option for global rights. Urocidin is a patented formulation of Mycobacterial Cell Wall-DNA Complex (MCC) developed by Bioniche. It is for the treatment of non-muscle-invasive bladder cancer that is currently undergoing phase-III clinical testing.
Under the agreement, Endo would pay Bioniche an up-front cash payment of $20 million and the potential for up to $110 million in additional payments, linked to the achievement of future clinical, regulatory, and commercial milestones. In addition, Bioniche will manufacture the product and receive a transfer price for supply.
David Holveck, President and CEO of Endo Pharmaceuticals, said: We are excited about the opportunity to expand our portfolio in bladder cancer treatment and enhance our late stage development pipeline. In August Endo plans to launch Valstar, for the treatment of bladder cancer. If successful in clinical development, Urocidin has the potential to extend and enhance our recent therapeutic expansion and strengthen the Valstar franchise.
Graeme McRae, Chairman, President and CEO of Bioniche, added: Endo Pharmaceuticals represents the optimal development and commercialization partner for Bioniche, given its understanding of the bladder cancer market and breadth of pharmaceutical industry experience. We look forward to advancing the Urocidin development and commercialization program in collaboration with the Endo team. Equally, we are very excited about the potential returns to Bioniche and its shareholders following commercialization of Urocidin.
Network Sites

Suppliers To This Sector
Browse A-Z
Solutions4Science
Temperature Mapping and Validation Services ...
Exploristics
Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Sta...
NeuroProof
Screening Services for Pre-Clinical Development of Neuro-Pharmaceuticals and Safety Pharmacology ...
DASGIP
Parallel Bioreactor Systems for the Cultivation of Bacterial, Phototrophic, Animal and Human Cells ...
BioKinetic Europe
Phase I/II Contract Research Organisation ...
Toxikon Europe
CRO Providing Preclinical Safety Studies for the Life Science Community ...
White Papers
Browse A-Z
GRACO's New FDA Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New Hydra-Clean
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New 1590 & 3150 Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
Customer Testimonial – Astra Zeneca
From the control room to the downstream processing area and with an eye on utilities servi ...
Hygienic Processing
From the control room to the downstream processing area and with an eye on utilities servi ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully